Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 77

1.

Author Correction: Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 17;10(1):1883. doi: 10.1038/s41467-019-09838-y.

2.

Crizotinib-induced immunogenic cell death in non-small cell lung cancer.

Liu P, Zhao L, Pol J, Levesque S, Petrazzuolo A, Pfirschke C, Engblom C, Rickelt S, Yamazaki T, Iribarren K, Senovilla L, Bezu L, Vacchelli E, Sica V, Melis A, Martin T, Xia L, Yang H, Li Q, Chen J, Durand S, Aprahamian F, Lefevre D, Broutin S, Paci A, Bongers A, Minard-Colin V, Tartour E, Zitvogel L, Apetoh L, Ma Y, Pittet MJ, Kepp O, Kroemer G.

Nat Commun. 2019 Apr 2;10(1):1486. doi: 10.1038/s41467-019-09415-3. Erratum in: Nat Commun. 2019 Apr 17;10(1):1883.

3.

Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy.

Castoldi F, Vacchelli E, Zitvogel L, Maiuri MC, Pietrocola F, Kroemer G.

Oncoimmunology. 2018 Oct 1;8(1):e1498285. doi: 10.1080/2162402X.2018.1498285. eCollection 2019.

4.

TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves.

Enot DP, Vacchelli E, Jacquelot N, Zitvogel L, Kroemer G.

Oncoimmunology. 2018 Aug 1;7(9):e1462431. doi: 10.1080/2162402X.2018.1462431. eCollection 2018.

5.

Organs on chip approach: a tool to evaluate cancer -immune cells interactions.

Biselli E, Agliari E, Barra A, Bertani FR, Gerardino A, De Ninno A, Mencattini A, Di Giuseppe D, Mattei F, Schiavoni G, Lucarini V, Vacchelli E, Kroemer G, Di Natale C, Martinelli E, Businaro L.

Sci Rep. 2017 Oct 6;7(1):12737. doi: 10.1038/s41598-017-13070-3.

6.

The ratio of CD8+/FOXP3 T lymphocytes infiltrating breast tissues predicts the relapse of ductal carcinoma in situ.

Semeraro M, Adam J, Stoll G, Louvet E, Chaba K, Poirier-Colame V, Sauvat A, Senovilla L, Vacchelli E, Bloy N, Humeau J, Buque A, Kepp O, Zitvogel L, André F, Mathieu MC, Delaloge S, Kroemer G.

Oncoimmunology. 2016 Aug 18;5(10):e1218106. eCollection 2016.

7.

A multi-perspective service evaluation exploring tuberculosis contact screening attendance among adults at a North London hospital.

MacLellan J, Wallace K, Vacchelli E, Roe J, Davidson R, Abubakar I, Southern J.

J Public Health (Oxf). 2016 Sep;38(3):e362-e367. Epub 2015 Sep 12.

8.

Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Jul 25;5(9):e1214790. eCollection 2016. Review.

9.

Autophagy induction for the treatment of cancer.

Pietrocola F, Pol J, Vacchelli E, Baracco EE, Levesque S, Castoldi F, Maiuri MC, Madeo F, Kroemer G.

Autophagy. 2016 Oct 2;12(10):1962-1964. Epub 2016 Aug 17.

10.

Contribution of RIP3 and MLKL to immunogenic cell death signaling in cancer chemotherapy.

Yang H, Ma Y, Chen G, Zhou H, Yamazaki T, Klein C, Pietrocola F, Vacchelli E, Souquere S, Sauvat A, Zitvogel L, Kepp O, Kroemer G.

Oncoimmunology. 2016 Mar 10;5(6):e1149673. doi: 10.1080/2162402X.2016.1149673. eCollection 2016 Jun.

11.

Inhibition of formyl peptide receptor 1 reduces the efficacy of anticancer chemotherapy against carcinogen-induced breast cancer.

Baracco EE, Pietrocola F, Buqué A, Bloy N, Senovilla L, Zitvogel L, Vacchelli E, Kroemer G.

Oncoimmunology. 2016 Feb 18;5(6):e1139275. doi: 10.1080/2162402X.2016.1139275. eCollection 2016 Jun.

12.

Yet another pattern recognition receptor involved in the chemotherapy-induced anticancer immune response: Formyl peptide receptor-1.

Vacchelli E, Ma Y, Baracco EE, Zitvogel L, Kroemer G.

Oncoimmunology. 2016 Mar 30;5(5):e1118600. doi: 10.1080/2162402X.2015.1118600. eCollection 2016 May.

13.

Caloric Restriction Mimetics Enhance Anticancer Immunosurveillance.

Pietrocola F, Pol J, Vacchelli E, Rao S, Enot DP, Baracco EE, Levesque S, Castoldi F, Jacquelot N, Yamazaki T, Senovilla L, Marino G, Aranda F, Durand S, Sica V, Chery A, Lachkar S, Sigl V, Bloy N, Buque A, Falzoni S, Ryffel B, Apetoh L, Di Virgilio F, Madeo F, Maiuri MC, Zitvogel L, Levine B, Penninger JM, Kroemer G.

Cancer Cell. 2016 Jul 11;30(1):147-160. doi: 10.1016/j.ccell.2016.05.016.

14.

Impact of Pattern Recognition Receptors on the Prognosis of Breast Cancer Patients Undergoing Adjuvant Chemotherapy.

Vacchelli E, Enot DP, Pietrocola F, Zitvogel L, Kroemer G.

Cancer Res. 2016 Jun 1;76(11):3122-6. doi: 10.1158/0008-5472.CAN-16-0294. Epub 2016 May 16. Review.

15.

Trial Watch-Immunostimulation with cytokines in cancer therapy.

Vacchelli E, Aranda F, Bloy N, Buqué A, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Dec 8;5(2):e1115942. eCollection 2016 Feb. Review.

16.

Immunosurveillance in esophageal carcinoma: The decisive impact of regulatory T cells.

Vacchelli E, Semeraro M, Adam J, Dartigues P, Zitvogel L, Kroemer G.

Oncoimmunology. 2015 Jul 1;5(2):e1064581. eCollection 2016 Feb.

17.

Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.

Garg AD, Galluzzi L, Apetoh L, Baert T, Birge RB, Bravo-San Pedro JM, Breckpot K, Brough D, Chaurio R, Cirone M, Coosemans A, Coulie PG, De Ruysscher D, Dini L, de Witte P, Dudek-Peric AM, Faggioni A, Fucikova J, Gaipl US, Golab J, Gougeon ML, Hamblin MR, Hemminki A, Herrmann M, Hodge JW, Kepp O, Kroemer G, Krysko DV, Land WG, Madeo F, Manfredi AA, Mattarollo SR, Maueroder C, Merendino N, Multhoff G, Pabst T, Ricci JE, Riganti C, Romano E, Rufo N, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Vacchelli E, Vandenabeele P, Vandenberk L, Van den Eynde BJ, Van Gool S, Velotti F, Zitvogel L, Agostinis P.

Front Immunol. 2015 Nov 20;6:588. doi: 10.3389/fimmu.2015.00588. eCollection 2015.

18.

Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1.

Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F, Yang H, Adjemian S, Chaba K, Semeraro M, Signore M, De Ninno A, Lucarini V, Peschiaroli F, Businaro L, Gerardino A, Manic G, Ulas T, Günther P, Schultze JL, Kepp O, Stoll G, Lefebvre C, Mulot C, Castoldi F, Rusakiewicz S, Ladoire S, Apetoh L, Bravo-San Pedro JM, Lucattelli M, Delarasse C, Boige V, Ducreux M, Delaloge S, Borg C, André F, Schiavoni G, Vitale I, Laurent-Puig P, Mattei F, Zitvogel L, Kroemer G.

Science. 2015 Nov 20;350(6263):972-8. doi: 10.1126/science.aad0779. Epub 2015 Oct 29.

19.

Autocrine signaling of type 1 interferons in successful anticancer chemotherapy.

Vacchelli E, Sistigu A, Yamazaki T, Vitale I, Zitvogel L, Kroemer G.

Oncoimmunology. 2015 Jul 25;4(8):e988042. eCollection 2015 Aug.

20.

Negative prognostic impact of regulatory T cell infiltration in surgically resected esophageal cancer post-radiochemotherapy.

Vacchelli E, Semeraro M, Enot DP, Chaba K, Poirier Colame V, Dartigues P, Perier A, Villa I, Rusakiewicz S, Gronnier C, Goéré D, Mariette C, Zitvogel L, Kroemer G.

Oncotarget. 2015 Aug 28;6(25):20840-50.

21.

Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.

Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Mar 2;4(4):e1008866. eCollection 2015 Apr. Review.

22.

Metabolomic analyses reveal that anti-aging metabolites are depleted by palmitate but increased by oleate in vivo.

Enot DP, Niso-Santano M, Durand S, Chery A, Pietrocola F, Vacchelli E, Madeo F, Galluzzi L, Kroemer G.

Cell Cycle. 2015 Aug 3;14(15):2399-407. doi: 10.1080/15384101.2015.1064206. Epub 2015 Jun 22.

23.

Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.

Vacchelli E, Pol J, Bloy N, Eggermont A, Cremer I, Fridman WH, Galon J, Marabelle A, Kohrt H, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Feb 3;4(1):e985940. eCollection 2015 Jan. Review.

24.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

25.

Trial watch: IDO inhibitors in cancer therapy.

Vacchelli E, Aranda F, Eggermont A, Sautès-Fridman C, Tartour E, Kennedy EP, Platten M, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 15;3(10):e957994. eCollection 2014 Nov. Review.

26.

Classification of current anticancer immunotherapies.

Galluzzi L, Vacchelli E, Bravo-San Pedro JM, Buqué A, Senovilla L, Baracco EE, Bloy N, Castoldi F, Abastado JP, Agostinis P, Apte RN, Aranda F, Ayyoub M, Beckhove P, Blay JY, Bracci L, Caignard A, Castelli C, Cavallo F, Celis E, Cerundolo V, Clayton A, Colombo MP, Coussens L, Dhodapkar MV, Eggermont AM, Fearon DT, Fridman WH, Fučíková J, Gabrilovich DI, Galon J, Garg A, Ghiringhelli F, Giaccone G, Gilboa E, Gnjatic S, Hoos A, Hosmalin A, Jäger D, Kalinski P, Kärre K, Kepp O, Kiessling R, Kirkwood JM, Klein E, Knuth A, Lewis CE, Liblau R, Lotze MT, Lugli E, Mach JP, Mattei F, Mavilio D, Melero I, Melief CJ, Mittendorf EA, Moretta L, Odunsi A, Okada H, Palucka AK, Peter ME, Pienta KJ, Porgador A, Prendergast GC, Rabinovich GA, Restifo NP, Rizvi N, Sautès-Fridman C, Schreiber H, Seliger B, Shiku H, Silva-Santos B, Smyth MJ, Speiser DE, Spisek R, Srivastava PK, Talmadge JE, Tartour E, Van Der Burg SH, Van Den Eynde BJ, Vile R, Wagner H, Weber JS, Whiteside TL, Wolchok JD, Zitvogel L, Zou W, Kroemer G.

Oncotarget. 2014 Dec 30;5(24):12472-508. Review.

27.

Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.

Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remédios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tüting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Préville X, Uzè G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, André F, Kroemer G, Zitvogel L.

Nat Med. 2014 Nov;20(11):1301-9. doi: 10.1038/nm.3708. Epub 2014 Oct 26.

PMID:
25344738
28.

Trial Watch: Toll-like receptor agonists in oncological indications.

Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Henrik Ter Meulen J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Aug 1;3:e29179. eCollection 2014.

29.

Trial watch: Immunostimulatory cytokines in cancer therapy.

Vacchelli E, Aranda F, Obrist F, Eggermont A, Galon J, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jun 3;3:e29030. eCollection 2014.

30.

Screening of novel immunogenic cell death inducers within the NCI Mechanistic Diversity Set.

Sukkurwala AQ, Adjemian S, Senovilla L, Michaud M, Spaggiari S, Vacchelli E, Baracco EE, Galluzzi L, Zitvogel L, Kepp O, Kroemer G.

Oncoimmunology. 2014 Apr 16;3:e28473. eCollection 2014.

31.

Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Aranda F, Vacchelli E, Obrist F, Eggermont A, Galon J, Hervé Fridman W, Cremer I, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 May 1;3:e28344. eCollection 2014. Review.

32.

Trial Watch: Chemotherapy with immunogenic cell death inducers.

Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Cremer I, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jan 1;3(1):e27878. Epub 2014 Mar 1. Review.

33.

Coffee induces autophagy in vivo.

Pietrocola F, Malik SA, Mariño G, Vacchelli E, Senovilla L, Chaba K, Niso-Santano M, Maiuri MC, Madeo F, Kroemer G.

Cell Cycle. 2014;13(12):1987-94. doi: 10.4161/cc.28929. Epub 2014 Apr 25.

34.

Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.

Aranda F, Vacchelli E, Eggermont A, Galon J, Fridman WH, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jan 1;3(1):e27297. Epub 2014 Feb 1.

35.

Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy.

Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Jan 1;3(1):e27048. Review.

36.

Regulation of autophagy by cytosolic acetyl-coenzyme A.

Mariño G, Pietrocola F, Eisenberg T, Kong Y, Malik SA, Andryushkova A, Schroeder S, Pendl T, Harger A, Niso-Santano M, Zamzami N, Scoazec M, Durand S, Enot DP, Fernández ÁF, Martins I, Kepp O, Senovilla L, Bauvy C, Morselli E, Vacchelli E, Bennetzen M, Magnes C, Sinner F, Pieber T, López-Otín C, Maiuri MC, Codogno P, Andersen JS, Hill JA, Madeo F, Kroemer G.

Mol Cell. 2014 Mar 6;53(5):710-25. doi: 10.1016/j.molcel.2014.01.016. Epub 2014 Feb 20.

37.

Trial Watch: Peptide vaccines in cancer therapy.

Aranda F, Vacchelli E, Eggermont A, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Dec 1;2(12):e26621. Epub 2013 Nov 4. Review.

38.

Trial Watch: Lenalidomide-based immunochemotherapy.

Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Nov 1;2(11):e26494. Epub 2013 Oct 21. Review.

39.

Trial Watch: Anticancer radioimmunotherapy.

Vacchelli E, Vitale I, Tartour E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Sep 1;2(9):e25595. Epub 2013 Jul 3. Review.

40.

Trial watch: Dendritic cell-based interventions for cancer therapy.

Vacchelli E, Vitale I, Eggermont A, Fridman WH, Fučíková J, Cremer I, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Oct 1;2(10):e25771. Epub 2013 Jul 29. Review.

41.

Trial Watch: Toll-like receptor agonists for cancer therapy.

Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Aug 1;2(8):e25238. Epub 2013 Jun 10. Review.

42.

Trial Watch: Immunostimulatory cytokines.

Vacchelli E, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Jul 1;2(7):e24850. Epub 2013 May 7. Review.

43.

Current trends of anticancer immunochemotherapy.

Vacchelli E, Prada N, Kepp O, Galluzzi L.

Oncoimmunology. 2013 Jun 1;2(6):e25396. Epub 2013 Jun 13. No abstract available.

44.

Trial watch: Oncolytic viruses for cancer therapy.

Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Jun 1;2(6):e24612. Epub 2013 Apr 16.

45.

ATP-dependent recruitment, survival and differentiation of dendritic cell precursors in the tumor bed after anticancer chemotherapy.

Ma Y, Adjemian S, Yang H, Catani JP, Hannani D, Martins I, Michaud M, Kepp O, Sukkurwala AQ, Vacchelli E, Galluzzi L, Zitvogel L, Kroemer G.

Oncoimmunology. 2013 Jun 1;2(6):e24568. Epub 2013 Apr 16.

46.

Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8.

Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckenstuhl C, Durchschlag M, Michaud M, Senovilla L, Sistigu A, Ma Y, Vacchelli E, Sulpice E, Gidrol X, Zitvogel L, Madeo F, Galluzzi L, Kepp O, Kroemer G.

Cell Death Differ. 2014 Jan;21(1):59-68. doi: 10.1038/cdd.2013.73. Epub 2013 Jun 21.

47.

Crosstalk between ER stress and immunogenic cell death.

Kepp O, Menger L, Vacchelli E, Locher C, Adjemian S, Yamazaki T, Martins I, Sukkurwala AQ, Michaud M, Senovilla L, Galluzzi L, Kroemer G, Zitvogel L.

Cytokine Growth Factor Rev. 2013 Aug;24(4):311-8. doi: 10.1016/j.cytogfr.2013.05.001. Epub 2013 Jun 17. Review.

PMID:
23787159
48.

Trial Watch: Adoptive cell transfer for anticancer immunotherapy.

Vacchelli E, Eggermont A, Fridman WH, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 May 1;2(5):e24238.

49.

Trial watch: DNA vaccines for cancer therapy.

Senovilla L, Vacchelli E, Garcia P, Eggermont A, Fridman WH, Galon J, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2013 Apr 1;2(4):e23803.

50.

Fluorescent biosensors for the detection of HMGB1 release.

Martins I, Kepp O, Menger L, Michaud M, Adjemian S, Sukkurwala AQ, Vacchelli E, Galluzzi L, Kroemer G.

Methods Mol Biol. 2013;1004:43-56. doi: 10.1007/978-1-62703-383-1_4.

PMID:
23733568

Supplemental Content

Loading ...
Support Center